Can AI Really Design New Drugs? Google DeepMind Spin-out Isomorphic Labs Explains

Drug discovery remains a complex, decade-long endeavor costing billions with a 90% clinical failure rate, necessitating a shift toward AI-first methodologies. Isomorphic Labs, represented by medicinal drug design lead Becky Paul and foundational AI research lead Michael Schaarschmidt, utilizes foundational models to move beyond mere protein structure prediction into active drug design. By integrating generative models and precise binding affinity predictions, the team aims to replace slow, traditional high-throughput screening with bespoke, model-designed molecules. This approach enables researchers to target previously "undruggable" proteins, such as KRAS, by accurately modeling atomic interactions and biological mechanisms. Ultimately, the goal is to compress the design cycle, increase clinical success rates, and reduce the massive capital requirements of drug development, potentially making personalized, rare-disease treatments economically viable in the future.